Contact the Editorial Desk

Editorial correspondence

Kiss Peptide welcomes correspondence on the research record: a citation quoted inaccurately, a regulatory reference that has been superseded, or a peer-reviewed study about kisspeptin or PT-141 that should be added to the references page. Corrections that improve accuracy are the most useful messages this desk receives.

The most actionable notes specify three things: the page they refer to, the exact passage in question, and a supporting citation — a DOI or PubMed ID wherever possible. That lets us verify a proposed change against the source quickly.

Notes about the FDA prescribing information for bremelanotide are especially welcome when the label has been updated, since regulatory documents can change and this desk aims to reflect current approval status.

Editorial mailbox: editors@kisspeptide.com

What this desk cannot do

Kiss Peptide is a literature digest, not a clinic or a vendor. It cannot:

• Advise on, recommend, or comment on human use of any peptide discussed here.
• Suggest a dose, schedule, or route of administration for any individual.
• Diagnose a condition or judge whether a research finding applies to a specific person.
• Sell, source, recommend, or help locate any compound from any supplier.
• Advise anyone on whether bremelanotide is appropriate for their medical situation — that question belongs with a licensed prescriber.
• Answer requests from athletes about using these compounds given the WADA framework around non-approved peptides.

Readers seeking medical guidance should consult a licensed clinician in their own jurisdiction. Editorial responses are not guaranteed and may be delayed; the mailbox is monitored intermittently.